Conference Day Two
Thursday, March 27, 2025
7:30 am Check-In & Coffee
8:20 am Chair’s Opening Remarks
Cultivating Academic, Biotech & Pharma Collaborations to Revolutionize Treg Therapeutic Development
8:30 am Panel Discussion: Driving Industry Collaborations to Unlock New Therapeutic Opportunities
Synopsis
- Evaluating public and private partnerships between pharma and biotech companies institutions
- Discussing ideal criteria for company collaborations and investment to improve discovery efficiency
- Highlighting key strategies from successful collaborations to direct and refine future collaborative efforts
9:30 am Keynote Presentation: Leveraging Clinical Polyclonal Tregs for the Development of Modified & Engineered Tregs
Synopsis
- Harnessing effective data from clinically derived polyclonal Tregs
- Showcasing long-term clinical Type 1 Diabetes data
- Utilizing polyclonal Tregs to shape the next generation of Treg therapies
10:00 am Morning Break & Networking
Treg Cell Therapy
Leveraging CAR-Tregs to Enhance Potency, Persistence & Safety
11:00 am Developing CAR-Treg Therapies to Enhance Clinical Efficacy
Synopsis
- Discussing Treg engineering strategies to improve safety and efficacy
- Revealing insights into the ongoing LIBERATE clinical trial
- Exploring Treg stability and pharmacokinetics to enhance safety
11:30 am Designing CAR Tregs for Neurodegenerative Disease Therapy
Synopsis
- Targeting disease sites in the CNS
- Utilizing disease modifying molecules to improve therapeuticactivity
- Harnessing CARs to improve Treg persistence in the CNS
Treg Modulators
Exploring IL-2 Fusion Proteins & Muteins as Treg Modulators
11:00 am Analyzing Natural Glycosylated PEG-IL2v with Treg Bias for ALS & Autoimmune Diseases
Synopsis
- Designing the best IL-2v for chronic inflammatory diseases
- CTM201 is the first long-acting PEG-IL2v without compromising its bioactivity
- Examining the PK/PD and safety profiles of CTM201 in ALS patients
11:30 am Exploring CUE-401: A Novel TGF-β/ IL-2 Fusion Protein for the Induction & Expansion of FOXP3+ Regulatory T-Cells
Synopsis
- TGF-β and IL-2 are two key signals for the induction of regulatory T-cell populations
- CUE-401 is a novel TGF-β and IL-2 directed therapy that is being developed for the selective expansion of regulatory T-cells in vivo
- Exploring the activity and mechanism of action of CUE-401
12:00 pm Lunch Break & Networking
Refining the Manufacturing Process for Successful Treg Cell Therapy Scalability
1:00 pm Elevating the Manufacturing Process to Identify & Produce Safe Cell Therapy Doses
Synopsis
Outlining methods and approaches for the development of a closed and automated manufacturing process for Tr1-based cell therapies
Detailing the operational and regulatory requirements for utilizing donor cell pooling as a technique to improve therapeutic outcomes
Improving the security and robustness of the manufacturing process to consistently produce the appropriate dose
1:30 pm Generating Potent, Stable & Off-the-Shelf Synthetic Tregs from CD4+ Tconv for the Treatment of Colitis & Beyond
Synopsis
- Outlining the process of converting CD4 cells to synthetic Tregs (synTregs) via gene engineering
- Highlighting the benefits of synTregs compared to tTregs as cellular therapy
- Showcasing preclinical efficacy data from GvHD and colitis mouse models
2:00 pm Optimizing Treg Cell Expansion to Produce High-Quality Tregs
Synopsis
- Exploring methods of Treg expansion to improve scalability
- Identifying the ideal amount of Treg expansion to produce quality treatments
- Assessing approaches to prevent differentiation during Treg expansion
Designing Enhanced Immunomodulators to Improve Therapeutic Outcomes
1:00 pm Exploring Strategies to Mitigate Immune Dysregulation Mediated by Foxp3 Deficiency
Synopsis
- Targeting dysregulated signaling pathways in Foxp3-deficient Tregs
- Metabolic reprogramming to harness fatal autoimmunity
- Examining the role of IL2 signaling and Foxp1 in maintaining Foxp3-deficient Treg identity
1:30 pm The Poly-Pharmacology of S-4321, a Dual Cell -Bi- Directional PD-1 Agonist for the Treatment of Autoimmune & Inflammatory Diseases
Synopsis
- Discussing the tole of inhibitory receptor in the maintenance of immune tolerance
- Highlight ongoing research initiatives on dual cell bidirectional PD-1 agonist
- Explore the intersection of Treg biology and PD-1 agonism
2:00 pm Clinical Evidence of Immune Tolerance Induction: Examples from Celiac Disease & Multiple Sclerosis
Synopsis
- Exploring antigen targeting to effectively modulate a range of autoimmune diseases
- Translating preclinical biology to clinical evidence: the role of regulatory T-cells in establishing immune tolerance
- Unveiling clinical evidence of regulatory T-cell activity (including bystander/linked suppression)
2:30 pm Afternoon Break & Networking
Identifying the Appropriate Target Population & Selecting the Correct Disease Indications
3:00 pm Discussing Considerations when Determining Disease Indication
Synopsis
- Exploring disease analysis methods to identify indications in which Tregs can be effectively utilized
- Effectively unravelling complex mechanisms of action to find an appropriate disease indication
- Identifying the ideal disease to be tackled by Treg cell therapies and Treg modulators
3:30 pm Determining the Right Patient Population to Improve Clinical Outcomes
Synopsis
- Discussing methods to sufficiently analyze patient characteristics to identify populations that will benefit TRACT kidney transplant treatments
- Identifying the right patient population when designing a clinical trial
- Providing an update on kidney transplant phase II